肺癌脑组织转移为何对奥希替尼耐药？答案在这里

PC9-BrM肠道体内成瘤后重新小组建应用领域osimertinib和RAR抑制放射治疗，脊髓小组织切片CK7皮肤上

除上述结果外，Biswas的团队也通过实验证明S100A9-ALDH1A1连杆对于心脏病肝细胞脊髓部移转到的基因表述，即肺小组织内以及移转到到骨小组织的心脏病肝细胞的活到转化并不发挥作用S100A9-ALDH1A1连杆。同时，他们查阅了EGFR特异性心脏病患儿的心脏病小组织样本，并样品S100A9的表述，结果找到 癌细胞肝细胞内S100A9表述水平与患儿脊髓移转到和更是短的无复发生存期普遍存在正向系统性性。

总的来说，Biswas的团队基于临床中所45%的EGFR特异性心脏病患儿经常出现脊髓移转到这一现像，以及目前第三代药品osimertinib的应用领域情况，为了让病毒感染肠道构建心脏病脊髓移转到仿真及一系列实验揭示了， S100A9是osimertinib脑膜炎的心脏病肝细胞展开脊髓移转到的“特派联络员”，它通过调控ALDH1A1-RA连杆从而促成癌细胞肝细胞在脊髓部的活到和转化。

当然，这个研究工作也落实到了诊断和放射治疗层次，提示了osimertinib放射治疗前癌细胞肝细胞内S100A9的表述情况可预测放射治疗后脊髓移转到发生的危险性，osimertinib与RAR抑制的重新小组建应用领域并不需要提升脊髓部移转到癌细胞肝细胞的去除效率。

参考文献：

1.H. Sung, J. Ferlay, R. L. Siegel, M. Laversanne, I. Soerjomataram, A. Jemal, et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021;71(3):209-49.

2.Y. Shi, J. S. Au, S. Thongprasert, S. Srinivasan, C. M. Tsai, M. T. Khoa, et al. A prospective, molecular epidemiology study of EGFR mutations in Asian patients with advanced non-small-cell lung cancer of adenocarcinoma histology (PIONEER). J Thorac Oncol. 2014;9(2):154-62.

3.J. Rotow, T. G. Bivona. Understanding and targeting resistance mechanisms in NSCLC. Nat Rev Cancer. 2017;17(11):637-58.

4.J. G. Paez, P. A. Janne, J. C. Lee, S. Tracy, H. Greulich, S. Gabriel, et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science. 2004;304(5676):1497-500.

5.S. S. Ramalingam, J. Vansteenkiste, D. Planchard, B. C. Cho, J. E. Gray, Y. Ohe, et al. Overall Survival with Osimertinib in Untreated, EGFR-Mutated Advanced NSCLC. N Engl J Med. 2020;382(1):41-50.

6.Z. Piotrowska, H. Isozaki, J. K. Lennerz, J. F. Gainor, I. T. Lennes, V. W. Zhu, et al. Landscape of Acquired Resistance to Osimertinib in EGFR-Mutant NSCLC and Clinical Validation of Combined EGFR and RET Inhibition with Osimertinib and BLU-667 for Acquired RET Fusion. Cancer Discov. 2018;8(12):1529-39.

7.A. K. Biswas, S. Han, Y. Tai, W. Ma, C. Coker, S. A. Quinn, et al. Targeting S100A9-ALDH1A1-retinoic acid signaling to suppress brain relapse in EGFR-mutant lung cancer. Cancer Discov. 2022.